If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-19. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Indenture, also known as bonded labour or debt bondage, is a form of unfree labour in which a person works to pay off a debt by pledging themself as collateral. The services required to repay the debt, and their duration, may be undefined. Debt bondage can be passed on from generation to generation, with children required to pay off their progenitors' debt. Debt bondage is most prevalent in South Asia, and is the most widespread form of slavery today. Money marriage refers to a marriage where a child, usually a girl, is married off to settle debts owed by their parents. The Chukri system is a debt bondage system found in parts of Bengal where a woman or girl can be coerced into prostitution in order to pay off debts.
=== Jewish === Ahavas Israel - Founded in New York in 1890. Paid sick and death benefits for members and their wives. The emblem was a pair of clasped hands. Founders included Masons, Oddfellows, members of the Sons of Benjamin and the Independent Order of B'rith Abraham. American Star Order - Founded in New York in 1884, this was an order for Romanian American Jews and their wives. In 1899 had 5,500 members, half of which were female. Paid sickness and death benefits. Motto: "Charity, Harmony, and Brotherly Love". The emblem was a five-pointed star containing three Hebrew letters with the Roman numeral XIII below and the letter G above. B'nai Zion - also known as the Order of the Sons of Zion, B'nai Zion was founded in 1908 as the first explicitly Zionist fraternal order. Membership open to non-Jews since at least 1979. Had a benefit membership of 3,619 in 57 lodges in 1923. Had 24,000 members in the late 1960s, 40,000 in 115 chapters in 1979. 34,000 members in 1989. Headquarters in 1923 at 44 E. 23rd Street, New York City. Current headquarters at 136 East 39th Street. Licensed to sell insurance in 11 states, benefits include hospitalization and medical policies and retirement plans. Zionist work through B'nai Zion Foundation: sells Israel Bonds, sponsored Kfar B'nau Zion agricultural settlement with 500 members, an artist colony near Haifa, school of applied arts and hostel for art students, also built home for mentally challenged children in Israel.
Photograph A. – Open rhinoplasty: At rhinoplasty's end, after the plastic surgeon has sutured (closed) the incisions, the corrected (new) nose will be dressed, taped, and splinted immobile to permit the uninterrupted healing of the surgical incisions. The purple-ink guidelines ensured the surgeon's accurate cutting of the defect correction plan. Photograph B. – Open rhinoplasty: The new nose is prepared with paper tape in order to receive the metal nasal-splint that will immobilize it to maintain its correct shape as a new nose.
At the end of the month, it opened a unit in Seoul (owned by 2F Enterprises) and one in Brunei (owned by a subfranchise of A&W Singapore). As of June 1998, A&W only had two restaurants in Mexico. The Cairo branch opened on August 1, 1998, under local franchise American Egyptian Foreign Investments, with Egypt becoming the seventeenth country outside of the United States to open a location. The first co-branded A&W restaurant, tied with Mexican food chain Amigos, opened in Lincoln in 1997. There were plans to increase the amount of co-branded locations across Nebraska by four in the second half of 1998. The goal of the co-branded restaurant was to allure more customers who did not prefer Mexican food. On March 16, 1999, it announced the opening of a restaurant in Dhaka with franchisee Global Supplies Limited due in September that year, with four more planned. The restaurant in Lodi took part in a world record for the largest root beer float of 2562.5 gallons on June 19, 1999, the eve of the eightieth anniversary of the chain. That same year, the chain attempted to enter the Korean market by finding local partners, aiming to grow in the Korean market in the first half of 2000. The plan was ultimately shelved. A&W merged with Long John Silver's to form Yorkshire Global Restaurants based in Lexington, Kentucky in March 1999. Kevin Bazner was promoted president of the chain in July. In 2000, Yorkshire agreed to test multi-branded locations with Tricon Global Restaurants. A grocery location opened in February that year in Idaho.
Historically, the birth rate of teenagers peaked in the late 1950s and early 1960s. However, at that time, most teenage parents were married. In the early twenty-first century, nine in ten births to the age group 15-19 are to unmarried mothers. Social norms have changed; it is now not unusual for teenagers to delay or avoid sexual intercourse altogether. Younger teenagers are more likely to practice abstinence than their older counterparts. A report published by the Center for Disease Control and Prevention (CDC) in early 2018 found the number of high school students who have had sex fell from 47% in 2005 down to 41% in 2015, with the most dramatic drop taking place between 2013 and 2015. On top of that, among never-married teens who have had sex, overwhelming majorities reported they used contraception the first time they did it. There are a few reasons for this. First, Millennials and Generation Z are more focused on the consequences of sex than their predecessors were. Second, there has been growing concern over unwanted sexual advances, especially in the wake of the Me-too movement. Writing for The Spectator, Douglas Murray dubbed this the "sexual counter-revolution." Third, as a consequence of the precarious contemporary economy, young adults today are more likely to be living with their parents rather than on their own, with a romantic partner, or a spouse. A 2016 analysis by the CDC discovered that teenage birthrates nosedived between 1991, when they reached a crisis point, and 2014, when they dropped by 60%, a record low.
Sources: en.wikipedia.org
The radiological evaluation through HRCT is an essential point in the diagnostic pathway in IPF. HRCT is performed using a conventional computed axial tomographic scanner without injection of contrast agents. Evaluation slices are very thin, 1–2 mm (0.039–0.079 in). Typical HRCT of the chest of IPF demonstrates fibrotic changes in both lungs, with a predilection for the bases and the periphery. According to the joint ATS/ERS/JRS/ALAT 2011 guidelines, HRCT is an essential component of the diagnostic pathway in IPF which can identify UIP by the presence of:
== Principles of saw chain operation == Saw chains operate by being propelled around a guide bar, removing material from the kerf by cutting chips from the side and bottom. In order to operate properly, the depth to which each tooth cuts must be limited to avoid it binding in the wood. Scratcher chain, like the teeth on a hand saw, simply uses a multitude of teeth to prevent individual teeth from sinking too far in without undue pressure on the bar. Chipper chain, and all subsequent designs, incorporate a depth gauge (also known as a "raker") on each cutter link to limit depth of cut on each tooth. This has two distinct advantages over scratcher chain – it enables the use of fewer cutters per unit length of chain, which allows for shorter downtime for sharpening, and produces a more "open" chain layout, allowing far better clearance of chips and debris from the kerf. Individual depth gauges on each tooth also enable the use of skip chain. Skip or semi-skip chain has a further reduction in the number of teeth and is used for applications where much debris is produced, such as ripping or cross-cutting very large sections of wood. Skip chain also absorbs less power from the motor per unit length of chain than full-complement chain, allowing the use of a longer bar/chain combination on any given motor.
=== Dry co-micronization === Dry co-micronization is a nanomilling approach in which the drug substance is milled in a dry state together with GRAS excipients in a single unit operation. The excipients form a protective dispersion matrix around the sub-micron drug particles, preventing the surface-energy-driven reaggregation that otherwise dominates dry submicron powders, and yielding a free-flowing powder that can be tableted or encapsulated without further drying or downstream processing. The most widely commercialized dry co-micronization platform is SoluMatrix Fine Particle Technology, developed by iCeutica and acquired in 2011 by Iroko Pharmaceuticals. The platform has been used to formulate three U.S. Food and Drug Administration–approved low-dose non-steroidal anti-inflammatory drugs: Zorvolex (diclofenac, approved October 2013), Tivorbex (indomethacin, approved February 2014), and Vivlodex (meloxicam, approved October 2015). Each product was approved at a total daily dose 20–35% below the equivalent conventionally-formulated NSAID, on the basis that the increased dissolution rate of sub-micron particles permits comparable analgesic efficacy at lower systemic exposure. Unlike wet media milling, dry co-micronization requires no aqueous suspension or downstream drying step, shortening the unit-operation chain at the cost of constraining the formulation to excipients compatible with high-energy dry impact.
==== MeSH D13.695.740 – pyrimidine nucleotides ==== MeSH D13.695.740.050 – apurinic acid MeSH D13.695.740.246 – cytosine nucleotides MeSH D13.695.740.246.050 – arabinofuranosylcytosine triphosphate MeSH D13.695.740.246.115 – cyclic cmp MeSH D13.695.740.246.150 – cytidine diphosphate MeSH D13.695.740.246.150.180 – cytidine diphosphate choline MeSH D13.695.740.246.150.210 – cytidine diphosphate diglycerides MeSH D13.695.740.246.370 – cytidine monophosphate MeSH D13.695.740.246.370.250 – cytidine monophosphate n-acetylneuraminic acid MeSH D13.695.740.246.400 – cytidine triphosphate MeSH D13.695.740.246.425 – deoxycytosine nucleotides MeSH D13.695.740.246.425.300 – deoxycytidine monophosphate MeSH D13.695.740.600 – pyrimidine dimers MeSH D13.695.740.706 – thymine nucleotides MeSH D13.695.740.706.788 – thymidine monophosphate MeSH D13.695.740.850 – uracil nucleotides MeSH D13.695.740.850.210 – deoxyuracil nucleotides MeSH D13.695.740.850.210.200 – fluorodeoxyuridylate MeSH D13.695.740.850.600 – uridine diphosphate MeSH D13.695.740.850.600.677 – uridine diphosphate sugars MeSH D13.695.740.850.600.677.100 – uridine diphosphate n-acetylgalactosamine MeSH D13.695.740.850.600.677.120 – uridine diphosphate n-acetylglucosamine MeSH D13.695.740.850.600.677.150 – uridine diphosphate n-acetylmuramic acid MeSH D13.695.740.850.600.677.300 – uridine diphosphate galactose MeSH D13.695.740.850.600.677.350 – uridine diphosphate glucose MeSH D13.695.740.850.600.677.375 – uridine diphosphate glucuronic acid MeSH D13.695.740.850.600.677.800 – uridine diphosphate xylose MeSH D13.695.740.850.877 – uridine monophosphate MeSH D13.695.740.850.950 – uridine triphosphate
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.